Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Department of Justice
AstraZeneca
Boehringer Ingelheim
Accenture
Express Scripts
Merck
Dow
Julphar

Generated: December 13, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ESTRAMUSTINE PHOSPHATE SODIUM

« Back to Dashboard

Clinical Trials for Estramustine Phosphate Sodium

Trial ID Title Status Sponsor Phase Summary
NCT00002721 Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Completed University of New Mexico Phase 1 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of doxorubicin plus estramustine in treating patients with metastatic recurrent prostate cancer that does not respond to hormone therapy.
NCT00002775 Docetaxel Plus Estramustine in Treating Patients With Metastatic Prostate Cancer Unknown status Herbert Irving Comprehensive Cancer Center Phase 1/Phase 2 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining docetaxel and estramustine in treating patients who have metastatic prostate cancer.
NCT00002855 Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed National Cancer Institute (NCI) Phase 3 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
NCT00002855 Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer Completed M.D. Anderson Cancer Center Phase 3 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining hormone therapy with chemotherapy and androgen suppression may kill more tumor cells. It is not yet known which treatment regimen is more effective for prostate cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of chemotherapy plus hormone therapy versus androgen suppression alone as initial therapy in patients with prostate cancer that is metastatic or that cannot be removed surgically.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Estramustine Phosphate Sodium

Condition Name

Condition Name for Estramustine Phosphate Sodium
Intervention Trials
Prostate Cancer 26
Lymphoma 2
Hormone-resistant Prostate Cancer 1
Sarcoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Estramustine Phosphate Sodium
Intervention Trials
Prostatic Neoplasms 27
Adenocarcinoma 2
Lymphoma 2
Kidney Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Estramustine Phosphate Sodium

Trials by Country

Trials by Country for Estramustine Phosphate Sodium
Location Trials
United States 219
Canada 3
Puerto Rico 2
South Africa 1
Peru 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Estramustine Phosphate Sodium
Location Trials
New York 16
Illinois 10
New Jersey 8
Michigan 8
Massachusetts 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Estramustine Phosphate Sodium

Clinical Trial Phase

Clinical Trial Phase for Estramustine Phosphate Sodium
Clinical Trial Phase Trials
Phase 3 6
Phase 2 17
Phase 1/Phase 2 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Estramustine Phosphate Sodium
Clinical Trial Phase Trials
Completed 21
Unknown status 5
Active, not recruiting 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Estramustine Phosphate Sodium

Sponsor Name

Sponsor Name for Estramustine Phosphate Sodium
Sponsor Trials
National Cancer Institute (NCI) 21
Eastern Cooperative Oncology Group 4
M.D. Anderson Cancer Center 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Estramustine Phosphate Sodium
Sponsor Trials
Other 35
NIH 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Teva
UBS
Citi
US Army
Deloitte
Mallinckrodt
Daiichi Sankyo
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.